Yi-Jia Lin1, Chiung-Ju Chen2,3, Shu-Ching Hsueh4, Mei-Hui Lee5, Shu-Fen Peng6,7, Hsu-Feng Lu8,9, Kung-Wen Lu10, Wen-Wen Huang6, Kuo-Ching Liu11, Yung-Liang Chen12, Yung-Luen Shih13,14, Jin-Cherng Lien15. 1. Department of Pathology, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C. 2. Department of Pathology and Laboratory Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C. 3. Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan, R.O.C. 4. Division of Hematology and Oncology, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C. 5. Department of Genetic Counseling Center, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 6. Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C. 7. Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C. 8. Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan, R.O.C. 9. Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. 10. College of Chinese Medicine, School of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C. 11. Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan, R.O.C. 12. Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, Taiwan, R.O.C. 13. Department of Pathology and Laboratory Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C.; t005524@ms.skh.org.tw jclien@mail.cmu.edu.tw. 14. School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan, R.O.C. 15. School of pharmacy, China Medical University, Taichung, Taiwan, R.O.C. t005524@ms.skh.org.tw jclien@mail.cmu.edu.tw.
Abstract
BACKGROUND/AIM: Demethoxycurcumin (DMC), one of the components of curcuminoids, has antitumor activities in many human cancer cells and is known to induce apoptosis in human leukemia cells. However, there are no reports showing the effects of DMC on the immune response in leukemia mice in vivo. Herein, we evaluated the impact of DMC on immune responses in WEHI-3-generated leukemia mice in vivo. MATERIALS AND METHODS: Fifty male BALB/c mice were separated randomly into five groups. Group I is normal mice, and groups II-V mice of generated leukemia by WEHI-3 cells. Group II-V mice were intraperitoneally injected with dimethyl sulfoxide (DMSO, as the positive control), 15, 30, and 60 mg/kg of DMC, respectively, every two days for 14 days. The body weight, blood, peritoneal fluid, liver, and spleen were individually analyzed. RESULTS: DMC did not significantly affect animal appearance and body weight. It decreased liver and spleen weight at a high dose. DMC did not affect the cluster of differentiation 3 (CD3) and CD19 cell populations but induced decrease of CD11b at 30 mg/kg treatment. However, DMC at low dose significantly increased the cluster of macrophage (Mac-3) cell populations, but at high dose it decreased them. DMC increased macrophage phagocytosis from peripheral blood mononuclear cells at 15 mg/kg treatment and peritoneal cavity at 15, 30 and 60 mg/kg of DMC treatments. DMC did not significantly affect the cytotoxic activity of natural killer (NK) cells. Furthermore, DMC decreased B and T cell proliferation at high doses. CONCLUSION: DMC elevated macrophage phagocytosis in leukemia mice in vivo.
BACKGROUND/AIM: Demethoxycurcumin (DMC), one of the components of curcuminoids, has antitumor activities in many human cancer cells and is known to induce apoptosis in human leukemia cells. However, there are no reports showing the effects of DMC on the immune response in leukemia mice in vivo. Herein, we evaluated the impact of DMC on immune responses in WEHI-3-generated leukemia mice in vivo. MATERIALS AND METHODS: Fifty male BALB/c mice were separated randomly into five groups. Group I is normal mice, and groups II-V mice of generated leukemia by WEHI-3 cells. Group II-V mice were intraperitoneally injected with dimethyl sulfoxide (DMSO, as the positive control), 15, 30, and 60 mg/kg of DMC, respectively, every two days for 14 days. The body weight, blood, peritoneal fluid, liver, and spleen were individually analyzed. RESULTS: DMC did not significantly affect animal appearance and body weight. It decreased liver and spleen weight at a high dose. DMC did not affect the cluster of differentiation 3 (CD3) and CD19 cell populations but induced decrease of CD11b at 30 mg/kg treatment. However, DMC at low dose significantly increased the cluster of macrophage (Mac-3) cell populations, but at high dose it decreased them. DMC increased macrophage phagocytosis from peripheral blood mononuclear cells at 15 mg/kg treatment and peritoneal cavity at 15, 30 and 60 mg/kg of DMC treatments. DMC did not significantly affect the cytotoxic activity of natural killer (NK) cells. Furthermore, DMC decreased B and T cell proliferation at high doses. CONCLUSION: DMC elevated macrophage phagocytosis in leukemia mice in vivo.